Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2025 08:19 ET | Source: Biomerica, Inc.

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Test for Home Use

10-minute home test detects early kidney damage in diabetic and hypertensive patientsHypertension affects roughly one-third of adults in the UAEDiabetes impacts approximately one in four UAE nationals...
August 04, 2025 16:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Agios Pharmaceuticals today announced that the Saudi Food and Drug Authority has approved PYRUKYND® for the treatment of adult patients with thalassemia
July 25, 2025 07:00 ET | Source: Sobi, Inc.

Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)

Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in...
November 18, 2024 07:50 ET | Source: VivoPower International PLC

VIVOPOWER’S TEMBO SECURES FULL ON ROAD HOMOLOGATION FOR ITS TEMBO TUSKER 100% ELECTRIC VEHICLES IN US$10 bn AUSTRALASIAN PICK UP TRUCK MARKET

Tembo Tusker is only the 2nd full electric utility vehicle pick up truck to receive full on road homologation VTA regulatory approval in Australia Tuskers can now be driven on road and off road in...
May 06, 2024 16:01 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Reports First Quarter 2024 Financial Results

FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 ...
March 14, 2024 16:15 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”)Accelerated approval was based on Phase 3 data demonstrating that Rezdiffra improved...
February 29, 2024 12:00 ET | Source: EzFill Holdings Inc.

EzFill Receives Approval from Three Miami Condo Associations to Offer Fueling to Residents of 600+ Units.

Will Be Resident’s Exclusive Mobile Fueling Provider MIAMI, FL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- EzFill Holdings, Inc. (“EzFill” or the “Company”) (NASDAQ: EZFL), a pioneer and emerging leader in...
January 18, 2024 03:00 ET | Source: Orphalan

Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease

Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease Paris, France 18 January, 2024 - Orphalan SA (“Orphalan” or “the Company”),...
November 02, 2023 10:37 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®

CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
October 18, 2023 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment

Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing InitiativeGreater Than 1 year Safety Exposure to...